학술논문

Origanum Sipyleum Methanol Extract in Combination with Ponatinib Shows Synergistic anti-Leukemic Activities on Chronic Myeloid Leukemia Cells.
Document Type
Article
Source
Nutrition & Cancer. 2022, Vol. 74 Issue 10, p3679-3691. 13p. 2 Charts, 4 Graphs.
Subject
*FLOW cytometry
*REVERSE transcriptase polymerase chain reaction
*DRUG efficacy
*CHRONIC myeloid leukemia
*ANTINEOPLASTIC agents
*APOPTOSIS
*PROTEIN-tyrosine kinase inhibitors
*PHYTOCHEMICALS
*CELL cycle
*GENE expression
*DRUG synergism
*TOXICITY testing
*CELL proliferation
*PLANT extracts
*CELL lines
*OREGANO
*PHARMACODYNAMICS
Language
ISSN
0163-5581
Abstract
Origanum sipyleum is used in folk medicine due to its anti-inflammatory, antimicrobial, and antioxidant properties. Ponatinib, an effective tyrosine kinase inhibitor in the treatment of chronic myeloid leukemia (CML), has severe side effects. Thus, we aimed to determine a novel herbal combination therapy that might not only increase the anti-leukemic efficacy but also reduce the dose of ponatinib in targeting CML cells. Origanum sipyleum was extracted with methanol (OSM), and secondary metabolites were determined by phytochemical screening tests. The cytotoxic effects of OSM on K562 cells were measured by WST-1 assay. Median-effect equation was used to analyze the combination of ponatinib and OSM (p-OSM). Apoptosis, proliferation, and cell-cycle were investigated by flow-cytometry. Cell-cycle-related gene expressions were evaluated by qRT-PCR. OSM that contains terpenoids, flavonoids, tannins, and anthracenes exhibited cytotoxic effects on K562 cells. The median-effect of p-OSM was found as synergistic; OSM reduced the ponatinib dose ∼5-fold. p-OSM elevated the apoptotic and anti-proliferative activity of ponatinib. Consistently, p-OSM blocked cell-cycle progression in G0/G1, S phases accompanied by regulations in TGFB2, ATR, PP2A, p18, CCND1, CCND2, and CCNA1 expressions. OSM enhanced the anti-leukemic activity of ponatinib synergistically via inducing apoptosis, suppressing proliferation, and cell-cycle. As a result, OSM might offer a potential strategy for treating patients with CML. [ABSTRACT FROM AUTHOR]